These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 30986169)

  • 21. Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy.
    Tan I; Malinzak M; Salama AKS
    J Immunother Cancer; 2018 Jul; 6(1):77. PubMed ID: 30064495
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Autoimmune Bell's Palsy Following Immunotherapy For Metastatic Melanoma: A Report of 2 Cases.
    Zieman D; Frankel AE
    J Immunother; 2019 Oct; 42(8):318-320. PubMed ID: 31318723
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ipilimumab treatment associated with myasthenic crises and unfavorable disease course.
    Derle E; Benli S
    Neurol Sci; 2018 Oct; 39(10):1773-1774. PubMed ID: 29948466
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute progressive neuropathy-myositis-myasthenia-like syndrome associated with immune-checkpoint inhibitor therapy in patients with metastatic melanoma.
    Möhn N; Sühs KW; Gingele S; Angela Y; Stangel M; Gutzmer R; Satzger I; Skripuletz T
    Melanoma Res; 2019 Aug; 29(4):435-440. PubMed ID: 30855529
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sequential Therapy with Nivolumab Followed by Ipilimumab Induces Complete Response in Metastatic Melanoma of the Lung but with Severe Hepatotoxicities.
    Furudate S; Fujimura T; Kambayashi Y; Hidaka T; Hashimoto A; Aiba S
    Case Rep Oncol; 2016; 9(3):644-649. PubMed ID: 27920696
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complete ophthalmoplegia in Ipilmumab and Nivolumab combination treatment for metastatic melanoma.
    Alnabulsi R; Hussain A; DeAngelis D
    Orbit; 2018 Oct; 37(5):381-384. PubMed ID: 29381409
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Autoimmune polyradiculitis due to combination immunotherapy with ipilimumab and nivolumab for the treatment of metastatic melanoma.
    Lasocki A; Smith K
    J Clin Neurosci; 2020 Apr; 74():240-241. PubMed ID: 31983645
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [An autopsy case of nivolumab-induced myasthenia gravis and myositis].
    Sawai T; Hosokawa T; Shigekiyo T; Ogawa S; Sano E; Arawaka S
    Rinsho Shinkeigaku; 2019 Jun; 59(6):360-364. PubMed ID: 31142711
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer.
    Williams TJ; Benavides DR; Patrice KA; Dalmau JO; de Ávila AL; Le DT; Lipson EJ; Probasco JC; Mowry EM
    JAMA Neurol; 2016 Aug; 73(8):928-33. PubMed ID: 27271951
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune checkpoint-mediated myositis and myasthenia gravis: A case report and review of evaluation and management.
    Kang KH; Grubb W; Sawlani K; Gibson MK; Hoimes CJ; Rogers LR; Lavertu P; Yao M
    Am J Otolaryngol; 2018; 39(5):642-645. PubMed ID: 29903623
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature.
    Reuss JE; Kunk PR; Stowman AM; Gru AA; Slingluff CL; Gaughan EM
    J Immunother Cancer; 2016; 4():94. PubMed ID: 28031822
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rational Combination of Parvovirus H1 With CTLA-4 and PD-1 Checkpoint Inhibitors Dampens the Tumor Induced Immune Silencing.
    Goepfert K; Dinsart C; Rommelaere J; Foerster F; Moehler M
    Front Oncol; 2019; 9():425. PubMed ID: 31192129
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy-Review of the Literature and Future Outlook.
    Möhn N; Beutel G; Gutzmer R; Ivanyi P; Satzger I; Skripuletz T
    J Clin Med; 2019 Oct; 8(11):. PubMed ID: 31653079
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination Nivolumab/Ipilimumab Immunotherapy For Melanoma With Subsequent Unexpected Cardiac Arrest: A Case Report and Review of Literature.
    Khoury ZH; Hausner PF; Idzik-Starr CL; Frykenberg MRA; Brooks JK; Dyalram D; Basile JR; Younis RH
    J Immunother; 2019 Oct; 42(8):313-317. PubMed ID: 31206394
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma.
    Scott ES; Long GV; Guminski A; Clifton-Bligh RJ; Menzies AM; Tsang VH
    Eur J Endocrinol; 2018 Feb; 178(2):173-180. PubMed ID: 29187509
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Myasthenia Gravis Induced by Immune Checkpoint Inhibitors.
    Becquart O; Lacotte J; Malissart P; Nadal J; Lesage C; Guillot B; Du Thanh A
    J Immunother; 2019 Oct; 42(8):309-312. PubMed ID: 31246640
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A case report of nivolumab-induced myasthenia gravis and myositis in a metastatic renal cell carcinoma patient.
    Nakanishi S; Nishida S; Miyazato M; Goya M; Saito S
    Urol Case Rep; 2020 Mar; 29():101105. PubMed ID: 31908963
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma.
    Murakami N; Borges TJ; Yamashita M; Riella LV
    Clin Kidney J; 2016 Jun; 9(3):411-7. PubMed ID: 27274826
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paraneoplastic dermatomyositis appearing after nivolumab therapy for gastric cancer: a case report.
    Shibata C; Kato J; Toda N; Imai M; Fukumura Y; Arai J; Kurokawa K; Kondo M; Takagi K; Kojima K; Ohki T; Seki M; Yoshida M; Suzuki A; Tagawa K
    J Med Case Rep; 2019 Jun; 13(1):168. PubMed ID: 31153385
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune checkpoint inhibitors in the onset of myasthenia gravis with hyperCKemia.
    Takamatsu K; Nakane S; Suzuki S; Kosaka T; Fukushima S; Kimura T; Miyashita A; Mukaino A; Yamakawa S; Watanabe K; Jinnin M; Komohara Y; Ihn H; Ando Y
    Ann Clin Transl Neurol; 2018 Nov; 5(11):1421-1427. PubMed ID: 30480036
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.